Evidence map›Paper›PMID 38647294›Full record

Trial reportAntimicrobial agents and chemotherapy2024

Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects.

Size Li, Xu Zhu, Guoying Cao, Jufang Shen, Xu Zhu, Jicheng Yu, Xiaojie Wu, Jufang Wu, Haijing Yang, Nanyang Li and 4 more

Abstract readRandomized Controlled TrialClinical Trial, Phase I
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Size Li *Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0009-0008-3809-0183
Xu Zhu *Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Guoying CaoClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Jufang ShenEVEREST MEDICINES, Shanghai, China.
Xu ZhuEVEREST MEDICINES, Shanghai, China.
Jicheng YuClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Xiaojie WuClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-0081-6507
Jufang WuClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Haijing YangClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Nanyang LiClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Yingying HuClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Jingjing WangClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Haihui HuangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-3803-5877
Jing ZhangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-2966-9149

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EVER206 (also known as SPR206) is a novel polymyxin analog that has shown

Indexed as

Anti-Bacterial AgentsPolymyxinsAdultArea Under CurveChinaDouble-Blind MethodEast Asian PeopleFemaleHalf-LifeHealthy VolunteersHumansMaleYoung AdultAnti-Bacterial AgentsPolymyxinsEVER206pharmacokineticspolymyxinssafetySPR206

Identifiers

PMID38647294
PMCPMC11620494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.